Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 299, Issue -, Pages 107-111Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2016.09.001
Keywords
Encephalitis; Autoimmune encephalitis; Low-dose IL-2; Regulatory T cell
Categories
Funding
- Seoul National University Hospital research fund [02-2016-0430, 25-2014-0040]
- National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea [2016R1C1B2011815]
- National Research Foundation of Korea [2016R1C1B2011815] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Low-dose interleukin-2 (IL-2) restores the balance of regulatory and effector T cells. We aimed to determine the feasibility of low-dose IL-2 as a treatment for refractory autoimmune encephalitis (AE). Ten patients who had received low-dose IL-2 were retrospectively identified. We observed an improvement in the modified Rankin Scale scores of six patients at the last follow-up compared with the scores at the initiation of low-dose IL-2 (p = 0.014). One patient experienced treatment-related grade 3 neutropenia. Overall, low-dose IL-2 is a feasible and relatively safe treatment for AE patients who are refractory to the first- and second-line immunotherapies. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available